Y
Y N Belenkov
Researcher at I.M. Sechenov First Moscow State Medical University
Publications - 56
Citations - 1111
Y N Belenkov is an academic researcher from I.M. Sechenov First Moscow State Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 26 publications receiving 505 citations.
Papers
More filters
Journal ArticleDOI
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society
Alexander R. Lyon,Susan Dent,Susannah Stanway,Helena M. Earl,Christine Brezden-Masley,Alain Cohen-Solal,Carlo G. Tocchetti,Javid Moslehi,John D. Groarke,Jutta Bergler-Klein,Vincent Khoo,Vincent Khoo,Li Ling Tan,Markus S. Anker,Stephan von Haehling,Christoph Maack,Radek Pudil,Ana Barac,Paaladinesh Thavendiranathan,Bonnie Ky,Tomas G. Neilan,Y N Belenkov,Stuart D. Rosen,Zaza Iakobishvili,Aaron L. Sverdlov,Ludhmila Abrahão Hajjar,Ariane Vieira Scarlatelli Macedo,Charlotte Manisty,Fortunato Ciardiello,Dimitrios Farmakis,Dimitrios Farmakis,Rudolf A. de Boer,Hadi Skouri,Thomas M. Suter,Daniela Cardinale,Ronald M. Witteles,Michael G. Fradley,Joerg Herrmann,Robert F. Cornell,Ashutosh Wechelaker,Michael J. Mauro,Dragana Milojkovic,Hugues de Lavallade,Frank Ruschitzka,Andrew J.S. Coats,Petar M. Seferovic,Ovidiu Chioncel,Thomas Thum,Johann Bauersachs,M. Sol Andres,David Wright,Teresa López-Fernández,Chris Plummer,Daniel J. Lenihan +53 more
TL;DR: In this paper, the authors presented a risk stratification proformas for oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
Journal ArticleDOI
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
Jelena Čelutkienė,Radek Pudil,Teresa López-Fernández,Julia Grapsa,Petros Nihoyannopoulos,Petros Nihoyannopoulos,Jutta Bergler-Klein,Alain Cohen-Solal,Dimitrios Farmakis,Dimitrios Farmakis,Carlo G. Tocchetti,Stephan von Haehling,Vassilis I. Barberis,Frank A. Flachskampf,Indrė Čeponienė,Eva Haegler-Laube,Thomas M. Suter,Tomas Lapinskas,Sanjay K Prasad,Rudolf A. de Boer,Kshama Wechalekar,Markus S. Anker,Zaza Iakobishvili,Zaza Iakobishvili,Chiara Bucciarelli-Ducci,Jeanette Schulz-Menger,Bernard Cosyns,Oliver Gaemperli,Y N Belenkov,Jean-Sébastien Hulot,Maurizio Galderisi,Patrizio Lancellotti,Jeroen J. Bax,Thomas H. Marwick,Ovidiu Chioncel,Tiny Jaarsma,Tiny Jaarsma,Wilfried Mullens,Massimo F Piepoli,Thomas Thum,Stephane Heymans,Stephane Heymans,Stephane Heymans,Christian Mueller,Brenda Moura,Frank Ruschitzka,José Luis Zamorano,Giuseppe M.C. Rosano,Andrew J.S. Coats,Riccardo Asteggiano,Petar M. Seferovic,Thor Edvardsen,Thor Edvardsen,Alexander R. Lyon +53 more
TL;DR: The role of echocardiographic parameters, including global longitudinal strain and three‐dimensional ejection fraction, are proposed and the protocol for baseline pre‐treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2‐targeted therapies such as trastuzumab and vascular endothelial growth factor tyrosine kinase inhibitors are presented.
Journal ArticleDOI
[Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment].
Viacheslav Mareev,I. V. Fomin,F. T. Ageev,Yu L Begrambekova,Y A Vasyuk,A. A. Garganeeva,G. E. Gendlin,M G Glezer,S V Gote,T V Dovzhenko,Zhanna Kobalava,N. A. Koziolova,A V Koroteev,Yu V Mareev,A G Ovchinnikov,N. B. Perepech,E I Tarlovskaya,A I Chesnikova,A O Shevchenko,G P Arutyunov,Y N Belenkov,A. S. Galyavich,S. R. Gilyarevskiy,O. M. Drapkina,Dmitry V. Duplyakov,Y M Lopatin,M. Y. Sitnikova,V V Skibitskiy,Evgeny Shlyakhto +28 more
Journal ArticleDOI
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Radek Pudil,Christian Mueller,Jelena Čelutkienė,Peter A. Henriksen,Dan Lenihan,Susan Dent,Ana Barac,Susanna Stanway,Javid Moslehi,Thomas M. Suter,Bonnie Ky,Martin Štěrba,Daniela Cardinale,Alain Cohen-Solal,Carlo G. Tocchetti,Dimitrios Farmakis,Dimitrios Farmakis,Jutta Bergler-Klein,Markus S. Anker,Stephan von Haehling,Y N Belenkov,Zaza Iakobishvili,Christoph Maack,Fortunato Ciardiello,Frank Ruschitzka,Andrew J.S. Coats,Petar M. Seferovic,Mitja Lainscak,Massimo F Piepoli,Ovidiu Chioncel,Jereon Bax,Jean-Sébastien Hulot,Hadi Skouri,Eva Simona Hägler-Laube,Riccardo Asteggiano,Teresa López Fernández,Rudolf A. de Boer,Alexander R. Lyon +37 more
TL;DR: Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio‐oncology biomarker research is discussed.
Journal ArticleDOI
Cancer diagnosis in patients with heart failure : epidemiology, clinical implications and gaps in knowledge
Pietro Ameri,Marco Canepa,Markus S. Anker,Y N Belenkov,Jutta Bergler-Klein,Alain Cohen-Solal,Dimitrios Farmakis,Teresa López-Fernández,Mitja Lainscak,Radek Pudil,Frank Ruschitska,Petar M. Seferović,Gerasimos Filippatos,Andrew J.S. Coats,Thomas M. Suter,Stephan von Haehling,Fortunato Ciardiello,Rudolf A. de Boer,Alexander R. Lyon,Carlo G. Tocchetti +19 more
TL;DR: This review paper summarizes the epidemiology and the prognostic implications of cancer occurrence in HF, the impact of pre‐existing HF on cancer treatment decisions and theimpact of cancer on HF therapeutic options, while providing some practical suggestions regarding patient care and highlighting gaps in knowledge.